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Introduction: The aim of this study was to explore the predictors of decline in walking ability in patients with
Alzheimer’s disease (AD).
Methods: The prospective REseau surla maladie ALzheimer FRançais (REAL.FR) study enrolled six hundred eighty four
community-dwelling AD subjects (71.20% women; mean age 77.84 Standard Deviation, SD, 6.82 years, Mini-Mental State
Examination 20.02, SD 4.23). Decline in walking ability was defined as the first loss of 0.5 points or more in the walking
ability item of the Activities of Daily Living scale (ADL), where higher score means greater independence, during the
four-years of follow-up. Demographic characteristics, co-morbidities, and level of education were reported at baseline.
Disability, caregiver burden, cognitive and nutritional status, body mass index, balance, behavioral and psychological
symptoms of dementia, medication, hospitalization, institutionalization and death were reported every six months
during the four years. Cox survival analyses were performed to assess the independent factors associated with decline in
walking ability.
Results: The mean incident decline in walking ability was 12.76% per year (95% Confidence Interval (CI) 10.86 to 14.66).
After adjustment for confounders, the risk of decline in walking ability was independently associated with older age
(Relative Risk, RR = 1.05 (95% CI 1.02 to 1.08)), time from diagnosis of dementia (RR = 1.16 (1.01 to 1.33)),
painful osteoarthritis (RR = 1.84 (1.19 to 2.85)), hospitalization for fracture of the lower limb (RR = 6.35 (3.02 to 13.37)),
higher baseline ADL score (RR = 0.49 (0.43 to 0.56)), and the use of acetylcholinesterase inhibitors (RR = 0.52 (0.28 to 0.96)).
Conclusions: The risk of decline in walking ability is predicted by older age, increased dementia severity, poor
functional score, and orthopedic factors and seems to be prevented by the use of acetylcholinesterase inhibitors
medication.Introduction
Longitudinal studies of subjects with Alzheimer’s disease
(AD) have mainly explored the gradual decline of cogni-
tive performance and the changes in behavioral domains.
The decline of ability to perform activities of daily living,
such as walking, has received less attention. However,
AD is also characterized by an early deterioration in mo-
bility [1] of significant practical importance [2-4].* Correspondence: rolland.y@chu-toulouse.fr
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reproduction in any medium, provided the orMobility limitation in AD patients results in approxi-
mately two or three times higher risk of falling than a
similar mobility limitation in cognitively intact older adults
[5]. Moreover, the ability to walk is also a key determinant
of an AD patient’s quality of life [6], institutionalization
[7], risk of death [8] and burden for the caregiver and the
community [9].
Numerous factors may explain the decline in walking
ability during the course of AD. Poor executive function
has been associated with poor physical performance.
In severe AD patients, extrapyramidal symptoms can beLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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events. Psychotropic treatment, weight loss, depressive
symptoms [12], behavior disturbance and poor balance
due to prolonged bed-rest, may also be associated with
gait disorders and loss of walking ability. To our know-
ledge, no study has previously reported the longitudinal
change in mobility using the walking item of the Activ-
ities of Daily Living (ADL) scale in people with AD and
investigated their predictors in community-dwelling AD
patients.
The identification of risk factors associated with future
mobility impairment represents a first step for the
optimization of preventive intervention in this vulner-
able population. Moreover, given the widespread use and
clinical relevance of the ADL scale, the present analyses
may provide results that may be easily implemented in
routine clinical practice. In fact, by showing that specific
risk factors may predict future decline of walking ability
in AD patients, we may hypothesize about the design of
effective interventions aimed at reversing this deterior-
ation. Thus, the aim of the present prospective study is
to investigate predictors of decline in walking ability in a
large cohort of AD patients, followed-up for four years.Methods
Study participants
We conducted secondary analyses of a large prospective
epidemiological study, the REAL.FR study (REseau sur la
maladie ALzheimer FRançais). The sampling and data
collection procedures have been previously described in
detail [13].
Briefly, from 2000 to 2002, 686 out-patients with AD
were enrolled. This study was carried out in 16 univer-
sity hospital departments of neurology, geriatrics or
psychiatry in 10 French cities to investigate the natural
history of AD. For inclusion, subjects had to meet the
National Institute of Neurological and Communicative
Diseases and Stroke/Alzheimer Disease and Related
Disorders Association (NINCDS-ADRDA) criteria for
probable or possible AD [14]. Additionally subjects
were required to be community-dwelling and to have a
caregiver who was willing to participate in the study.
Patients with a diagnosis of an illness with a life expect-
ancy less than 24 months were excluded. Subjects were
assessed at an outpatient consultation every six months
for four years. For the current study, two participants
were excluded from the analyses because of baseline
disability with walking as recorded in the relevant ADL
item. The REAL.FR study was supported by French
Ministry of Health Grants (PHRC 98-47 N and PHRC
18-05) and received ethical approval from the Advisory
Committee for the Protection of Persons participating
in Biomedical Research at the Toulouse UniversityHospital. It was conducted as an observation investiga-
tion and no signed informed consent was required.
Decline of walking ability
The ADL scale [15] was used to evaluate subjects’ func-
tional status. The six basic ADL items include: eating,
walking, continence, using the toilet, bathing and dress-
ing. The items are scored 0 (unable to do), 1 (do without
any human assistance) or 0.5 (need for assistance). De-
cline of walking ability was defined as the first loss of
0.5 points or more on the ‘walking ability’ item during
follow-up. Scoring was performed after examination of
the patient and direct inquiry with the caregiver every
six months in the day hospital over a four-year period.
Covariates
Age, gender and length of time since diagnosis were re-
ported. Caregiver and participants were asked whether
the subject had (yes/no) any of the following cardio-
vascular risk factors (diabetes mellitus, past or current
smoking, hypertension, dyslipidemia), cardiovascular dis-
ease (atrial fibrillation, angina, heart failure, myocardial
infarction, peripheral vascular disease), musculoskeletal
and painful osteoarthritis (back and/or legs) or other co-
morbidities (respiratory, sensorial, gastro-intestinal, kid-
ney, urinary, neurological or endocrine disease). The
presence of depression was obtained by direct inquiry
with the caregiver. Level of education (illiterate, elemen-
tary, primary, high school or post-graduate degree) was
recorded. At baseline, a cerebral tomography (CT-scan)
was performed and independently interpreted by both a
radiologist and a neurologist as follows: normal, atrophy
alone, lacuna or stroke or hypodensity of the white mat-
ter or other vascular lesion. CT-scans were reassessed by
both assessors in the case of conflicting interpretation.
Mortality was reported at the clinic visit every six
months over the four years and was ascertained by tele-
phone call to caregivers and/or primary-care physicians,
if necessary.
Some covariates considered in the present analyses were
computed as time-dependent variables: disability, caregiver
burden, cognitive and nutritional status, body mass index,
balance, behavioral and psychiatric symptoms of dementia
(BPSD), medication, hospitalization, and institutionalization
were reported at the clinic visit every six months.
Functional status was defined as the sum of the ADL
score excluding the walking item. Scores ranged from 0 to
5, with a lower score meaning worse function. The ADL
score was investigated as an independent variable since
walking ability modification may be affected by the overall
baseline functional status. Caregiver burden was assessed
using the Zarit scale [16]. Dementia severity was assessed
using the mini-mental status examination (MMSE <20, 17
to 22 or 22 to 27) [17], behavioral and psychiatric
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Neuro-Psychiatric Inventory (NPI) [18], and nutritional
status was evaluated using the Mini-Nutritional Assess-
ment (MNA) [19]. Body mass index (BMI =weight in
kilograms/squared height in kilogram meters) was also
calculated. Balance was assessed using the ‘one-leg bal-
ance’ test described by Vellas et al. [20]. The test was per-
formed by asking the subject to stand unassisted on one
leg as long as possible (eyes open, barefoot or not, using
whichever leg was spontaneously chosen by the subject).
The ‘one-leg balance’ test was reported as abnormal when
the subject was unable to stand on one leg for five seconds
or more [20]. The test was performed twice with the best
result used for the analysis. Caregivers were asked about
the patient’s current medication. Additionally, at assess-
ment interview, subjects were asked to bring with them all
their regular medication. Prescriptions of acetylcholineste-
rase (AChE) inhibitors (galantamine, donepezil or rivastig-
mine), psychotropic treatments (anxiolytics, neuroleptics,
serotonin reuptake inhibitors and other antidepressants),
anti-Parkinsonian treatment (dopamine agonist or dopa-
minergic agent) and vitamin D were collected and used as
additional covariates. NMDA-receptor antagonist (mem-
antine) was not available in France at that time, and, thus,
not considered for the present analyses. Subjects and care-
givers were asked about nursing-home admission and
hospitalization. The reason for hospitalization was re-
corded. Subjects who did not attend follow-up appoint-
ments were contacted by telephone and post if necessary.
Statistical analysis
Baseline characteristics were described using mean values ±
standard deviation (SD) and proportions for quantitative
and qualitative variables, respectively. Survival analyses
(Cox models) were performed to identify independent pre-
dictive factors of decline in walking ability, using relative
risk (RRs) and 95% confidence interval (CIs). Patients
were followed up until the first occurrence of the event
(decline in walking ability) or until the censor date (drop-
out, death, final endpoint). For time-dependent variables103 deaths
70 lost to follow-up
75 institutionalized
207 completed the 
684 subjects e
Figure 1 Flow chart of the REAL.FR population study during the four ye(disability, caregiver burden, cognitive and nutritional sta-
tus, body mass index, balance, behavioral and psychiatric
symptoms of dementia (BPSD), medication, hospitalization
and institutionalization), survival analyses were based on
the measure collected during the visit preceding the event,
except for hospitalization and institutionalization which
were considered regardless of the period when they oc-
curred [21]. The AChE inhibitor treatment (or the absence
of treatment) was taken into account during at least the
six-month period preceding the decline in walking ability.
For time-independent variables, analyses were based on
the measure collected at baseline. Cox proportional haz-
ards models with discrete times (because decline in walk-
ing ability occurs between the follow-up visits) using a
backwards selection procedure were performed with P
<0.20 as an entry criterion and P >0.05 as a removal criter-
ion. Two models (with or without the ADL introduced in
the initial model) were performed due to the fact that the
ADL score is strongly correlated with walking ability and
decline in walking ability may be both the cause and/or
the consequence of the ability to perform basic motor
tasks. Tests based on interaction with time were used to
ascertain the proportional hazards assumption for time-
constant variables (age, gender, level of education,
length of time from diagnosis of dementia, cardiovascu-
lar risk factors, cardiovascular disease or other co-
morbidities, CT). Statistical interactions were verified in
the final model. P-values were based on two-sided tests.
All statistical analyses were performed using SAS soft-
ware (version 9.3, SAS Institute Inc. Cary, NC, USA).
Results
The flow chart of the four-year REAL.FR prospective
study is shown in Figure 1. Among the 684 AD subjects
recruited at baseline, 207 attended the final follow up
visit at four years. During this period of observation, 103
participants died, 88 declined continuation in the study,
75 were institutionalized and 70 were lost to follow-up.
Compared to the patients followed over the four years,
the patients who did not completed the four-year follow88 withdrew from study
20moved house
50 medical problems
15 care giver problem
8 change in follow-up center
25 others
4 years follow-up
nrolled (M0)
ars of follow-up. REAL.FR, REseau sur la maladie ALzheimer FRançais.
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years; SD 6.74 versus 76.53; SD 6.81), were less fre-
quently women (68.72% versus 76.09%), were more dis-
abled (ADL = 5.33; SD 0.96 versus 5.67; SD 0.60), more
severely demented (MMS = 19.56; SD 4.34 versus 20.94;
SD3.84), had more behavior disturbance (NPI = 16.70;
SD 16.35 versus 12.69; SD 12.57), had more cardiovascu-
lar disease (29.52% versus 17.84%) and had more fre-
quently an abnormal one-leg balance test (19.17% versus
7.31%) (all P values <0.05). Baseline characteristics of
the study sample are summarized in Table 1. The inci-
dence decline in walking ability was 12.76% (95%CI,
10.86% to 14.66%) per year during the four years of
follow-up.
In the first model (Table 2), (after adjustment for con-
founders without the variable ADL), the following in-
dependent factors remained significantly associated with
decline in walking ability: older age (RR = 1.05 (1.02 to
1.08)), length of time from diagnosis of dementia (RR =
1.20 (1.05 to 1.37)), painful osteoarthritis (RR = 1.81
(1.17 to 2.78)), MNA score (RR = 1.45 (1.01 to 2.08)),
institutionalization (RR = 1.83 (1.03 to 3.25)), hospitalization
for lower limb fracture (RR = 5.80 (2.85 to 11.81)), MMSE
score between 16 to 20 versus >20 (RR = 1.07 (0.66 to
1.74)) and MMSE score <15 versus >20 (RR = 2.41 (1.54 to
3.75)), abnormal one leg balance test (RR = 2.25 (1.44
to 3.51)) and use of AChE inhibitors (RR = 0.48 (0.26 to
0.89)) (Table 2). In the second model (after adjustment for
all confounders including the variable ADL), the following
independent factors predicted the decline of the ability to
walk: older age (RR = 1.05 (1.02 to 1.08)), length of time
from diagnosis of dementia (RR = 1.16 (1.01 to 1.33)), pain-
ful osteoarthritis (RR = 1.84 (1.19 to 2.85)), hospitalization
for lower limb fracture (RR = 6.35 (3.02 to 13.37)), higher
ADL score (walking item excluded) (RR = 0.49 (0.43 to
0.56)) and use of AChE inhibitors remained in this final
model (RR = 0.52 (0.28 to 0.96)).
Discussion
This prospective study reports a high rate of decline in
walking ability in a community-dwelling AD population.
In this population, we reported a 12.76% annual inci-
dence of walking ability decline. After four years, about
one third (30.20%) of the remaining sample needed as-
sistance or had lost the ability to walk. We also show
that high risk of decline in walking ability is associated
with age, time since diagnosis of dementia, poor baseline
functional score and orthopedic factors but treatment
with AChE I appears protective.
The ability to walk has been reported to be a major
factor affecting quality of life in patients with dementia
[6]. Once a patient with AD has lost their ability to walk,
he/she is generally unable to regain it [22]. Delaying loss
of the ability to walk during the disease course for aslong as possible should be a goal in care planning. Previ-
ous studies have reported the significant changes that
occur in gait characteristics and gait speed [1]. Physical
performance tests [23] and specific scales, for example
the Unified Parkinson's Disease Rating Scale (UPDRS),
have been used to measure the changes in motor signs
in people with AD in longitudinal studies [24]. We be-
lieve that the reported rate of decline in walking ability
during a four-year follow-up, using the ADL score, pro-
vides clinically relevant data for potential interventional
studies aimed at slowing the decline in walking ability.
Age, time since diagnosis of dementia and poor base-
line functional score were expected results from this
study. Osteoarthritis [25] and hip fracture [26] are also
well-known and strong risk factors for disability, espe-
cially for the mobility domain and in the context of de-
mentia [27].
AChE inhibitors were found to be associated with a
lower risk of decline in walking ability and this factor
remained statistically significant in the different models.
A statistically significant improvement in global function
of patients treated by AChE inhibitors was previously re-
ported in some studies [28-30] but not in others [31].
Reviews and meta-analyses on the beneficial effect of the
AChE inhibitors on global functioning support only a
modest benefit in slowing decline in global function
[32]. These previous studies have addressed all ADL do-
mains that include heterogeneous items (urinary incon-
tinence, transfer, dressing, eating and walking). Then,
from an analytic perspective an improvement in just one
area might be clinically significant but statistically
masked by no effect in other functional domains. The
previous randomized clinical trials on global functional
score do not allow specific conclusions on the ability to
walk.
In our study, the suggested protective effect of AChE in-
hibitors on decline in walking ability raises several hypoth-
eses. Maintaining the ability to walk relies on many
factors, including cognitive function, balance and strength
but also physical training, behavior disturbance and envir-
onment. Some of these factors can be, at least in part, dir-
ectly or indirectly improved by AChE inhibitors. AChE
inhibitors have demonstrated a positive effect on cognition
[33,34] and studies suggest that galantamine may more
specifically improve attention and executive function [35].
Since AChE inhibitors improve gait velocity and reduce
gait variability [36], it is plausible to think that participants
on AChE inhibitors may develop a better gait strategy im-
proving their ability to adapt their gait pattern to unex-
pected situations, hence reducing their risk of falls [36].
Moreover, AChE inhibitors may impact walking ability in-
directly through a reduction in behavioral disturbance. In-
deed, AChE inhibitors have positive effects on a variety of
behavioral and psychiatric symptoms in AD, particularly
Table 1 Baseline characteristics of the subjects (n = 684)
Variables Values
Age (mean, SD, years) 77.84 (6.82)
Gender, female (%) 71.20
Level of education (% > primary school) 78.79
Age at diagnosis (mean, SD, years) 76.77 (7.00)
Cardiovascular risk factorsa (%) 59.65
Cardiovascular disease (%) 25.59
Painful osteoarthritis (%) 8.50
Depression (%) 37.17
Comorbidity (%)
0 28.09
1 37.96
≥ 2 33.95
MNA (%≤ 23.5) 33.03
Zarit score (mean, SD) 22.63 (15.87)
MMSE (mean, SD) 20.02 (4.23)
MMSE (%)
> 20 50.44
16 to 20 32.55
< 15 17.01
One leg balance test (% abnormal) 15.06
ADL score (mean, SD) 5.45 (0.87)
Weight (kg, mean, SD) 62.63 (12.76)
BMI (%)
< 20 13.33
20 to 25 43.26
25 to 30 33.63
≥ 30 9.78
NPI (mean, SD) 15.35 (15.30)
NPI (%)
Delusions 16.23
Hallucination 6.73
Agitation/aggression 36.99
Depression 38.74
Anxiety 42.25
Elation/euphoria 7.02
Apathy 53.51
Disinhibition 10.96
Irritability/lability 36.26
Aberrant motor behavior 21.78
Sleep disorder 14.62
Appetite disorder 22.11
Treatment (%)
AChE inhibitors 89.33
Psychotropic treatments 50.15
Table 1 Baseline characteristics of the subjects (n = 684)
(Continued)
Anti-Parkinsonian treatment 1.32
Computed tomography scan (%)
Normal 22.58
Atrophy alone 26.69
Lacuna or stroke 9.68
Hypodensity of the white matter 12.17
Other 8.65
CT scan not performed 20.23
aCardiovascular risk factors, diabetes mellitus, past or current smoking,
hypertension, dyslipidemia, cardiovascular disease, atrial fibrillation, angina,
heart failure, myocardial infarction, peripheral vascular disease; comorbidity,
respiratory, sensorial, gastro-intestinal, kidney, urinary, neurological disease,
endocrine, alcohol and other; anti-parkinsonian treatment, dopamine agonist
or dopaminergic agent; psychotropic treatments, anxiolytics, neuroleptics,
serotonin reuptake inhibitor and other antidepressants; AChE inhibitors, acetyl-
cholinesterase (AChE) inhibitors (galantamine, donepezil or rivastigmine); ADL,
Activities of Daily Living scale; BMI, body mass index; MNA, Mini-Nutritional As-
sessment, ≤23.5 versus >23.5; MMSE, Mini-Mental State Examination; NPI,
Neuro-Psychiatric Inventory.
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are often associated with low physical activity and physical
deconditioning, which may impact on the ability to walk
in the longer-term. The effect of AChE inhibitors on per-
ipheral neuromuscular mechanisms has been poorly
explored compared to the central effect and requires fur-
ther study and validation. However, the cholinergic neuro-
muscular junction of skeletal muscle is potentially a rich
source of amyloid-beta (Aβ) peptides and AD might have
systemic manifestations [38]. Moreover, AChE inhibitors
can generate fasciculation in rats [39] and experimental
electrophysiological data support an improvement in the
neuro-muscular properties of AD patients treated with
AChE inhibitors [40]. Finally, AChE inhibitors may attenu-
ate the negative effect of the systemic inflammatory re-
sponses through direct or indirect mechanisms. Increased
peripheral concentrations of inflammatory markers have
been reported in AD patients [41], and acetylcholine
can inhibit the production of pro-inflammatory cytokines
[42]. Basic research supports the theory that donepezil has
neuroprotective and cardioprotective effects via anti-
inflammatory mechanisms but other organs, such as the
muscle, may be affected [43].
This study has several limitations. First, discontinu-
ation of AChE inhibitors is a frequent event and may be
related to the acceleration of the functional decline.
Cognitive decline, anxiety, weight loss and hospita-
lization have been reported in this cohort to predict dis-
continuation of the AChE inhibitors [44]. To reduce this
limitation (AChE inhibitors discontinuation may be the
consequence of the functional decline or the decline of
the walking ability), we took into account discontinu-
ation of the AChE inhibitors at least six months prior to
Table 2 Univariate and multivariate logistic regression analyses of factors associated with the decline of walking
ability
Relative risk (95% confidence interval)
Univariate Stepwise backward regression
analysis
Stepwise backward regression
analysis
Model 1 Model 2
Age 1.06 (1.04 to 1.09) 1.05 (1.02 to 1.08) 1.05 (1.02 to 1.08)
Gender (reference group is male) 0.78 (0.54 to 1.12) - -
Length of time since the diagnosis of dementia 1.14 (1.01 to 1.28) 1.20 (1.05 to 1.37) 1.16 (1.01 to 1.33)
Cardiovascular risk factors 1.22 (0.88 to 1.70) - -
Cardiovascular disease 1.59 (1.11 to 2.27) - -
Painful osteoarthritis 1.62 (1.11 to 2.37) 1.81 (1.17 to 2.78) 1.84 (1.19 to 2.85)
Comorbidity
0 1 - -
1 1.07 (0.71 to 1.61)
≥ 2 1.52 (1.01 to 2.29)
MNA (≤23.5 versus >23.5) 2.01 (1.47 to 2.74) 1.45 (1.01 to 2.08) -
Institutionalization (yes versus no) 2.89 (1.77 to 4.73) 1.83 (1.03 to 3.25) -
Hospitalization for fracture of the lower extremity
(yes versus no)
4.27 (2.34 to 7.80) 5.80 (2.85 to 11.81) 6.35 (3.02 to 13.37)
Hospitalization for stroke (yes versus no) 2.14 (0.62 to 7.37) - -
Hospitalization for reason other than fracture or
stroke (yes versus no)
1.62 (1.11 to 2.35) - -
MMSE
> 20 1 1 -
16 to 20) 1.36 (0.89 to 2.06) 1.07 (0.66 to 1.74)
< 15 3.02 (2.06 to 4.44) 2.41 (1.54 to 3.75)
One leg balance test (abnormal versus normal) 3.10 (2.13 to 4.51) 2.25 (1.44 to 3.51) -
ADL score (walking item excluded) 0.49 (0.43 to 0.55) Not introduced in the model 1 0.49 (0.43 to 0.56)
BMI - -
< 20 1.22 (0.73 to 2.04)
20 to 25 1
25 to 30 1.03 (0.72 to 1.47)
> 30 1.76 (1.09 to 2.82)
Hallucination (yes versus no) 1.63 (0.94 to 2.86) - -
Apathy (yes versus no) 1.70 (1.23 to 2.37) - -
Aberrant motor behavior (yes versus no) 1.74 (1.27 to 2.39) - -
AChE inhibitors (yes versus no) 0.41 (0.25 to 0.66) 0.48 (0.26 to 0.89) 0.52 (0.28 to 0.96)
Psychotropic treatments (yes versus no) 1.36 (0.99 to 1.88) - -
Anti to Parkinsonian treatment (yes versus no) 2.32 (0.79 to 6.80) - -
Anti-parkinsonian treatment: dopamine agonist or dopaminergic agent; psychotropic treatments: anxiolytics, neuroleptics, serotonin reuptake inhibitor and other
antidepressants. AChE inhibitors, acetylcholinesterase inhibitors (rivastigmine or donepezil or galantamine); ADL, activities of daily living score with walking item
excluded (score over 5); BMI, body mass index; MNA, Mini-Nutritional Assessment <23.5 versus ≥24; MMS score, Mini-Mental state score.
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tors remained significantly associated with the decline in
walking ability in the final model which included the
ADL score. However, we cannot ignore the fact that
treatment with AChE inhibitors was only a marker of
better walking ability. Second, many factors, such aspain, low level of physical activity and deconditioned
balance because of prolonged bed-rest, were not as-
sessed in our study and may account for the decline
in walking ability. However, hospitalization and painful
osteoarthritis were taken into account in our analyses.
Third, selection bias could also have occurred because
Rolland et al. Alzheimer's Research & Therapy 2013, 5:52 Page 7 of 8
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specialized memory centers in France. The attrition rate
was high although similar to other cohorts of patients
with dementia. Characteristics of the patients lost to fol-
low up compromise the generalization of our results.
However, patients who refused to participate, were insti-
tutionalized or lost to follow up may have experienced a
higher rate of functional decline, probably leading to the
under-estimation of incident walking impairment. Fi-
nally, the choice of the ADL scale to assess the ability to
walk is open to criticism. The ADL is useful in the man-
agement of AD but the walking item may not be sensi-
tive to small but significant changes. Additional data on
physical performance such as the gait speed test would
have reinforced our results.
Conclusions
In conclusion, our results suggest that decline in walking
ability is associated with age, time since diagnosis of de-
mentia, overall functional status and orthopedic factors.
It is reduced by current prescription of AChE inhibitor
medication. Future studies should investigate whether
the benefit of AChE inhibitors on the ability to walk
may be reproduced and confirmed in ad hoc designed
interventional trials.
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